Trial Profile

Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etoposide (Primary) ; Gemtuzumab ozogamicin (Primary) ; Mitoxantrone (Primary) ; Corticosteroid; Diphenhydramine; Diphenhydramine; Methylprednisolone; Paracetamol; Paracetamol
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

20 Feb 2025 Status changed from active, no longer recruiting to completed.
22 Mar 2024 Planned End Date changed from 1 Dec 2029 to 22 Dec 2028.
22 Mar 2024 Status changed from completed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com